Drug news
FDA approves Revlimid for treatment of Mantle Cell Lymphoma
Celgene Corporation announced that the FDA has approved on 5 June 2013, the supplemental new drug application (sNDA) for Revlimid (lenalidomide), for the treatment of patients with Mantle Cell Lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
The approval of lenalidomide delivers a new option, and the first oral therapy in this area of lymphoma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.